In your arteries, yes. Plaque is now seen as an inflammatory disease, and damaged LDL cholesterol inside it can set off inflammation signals. But cholesterol and inflammation are separate risks. In people already taking statins, the inflammation marker hs-CRP predicted heart attacks and deaths better than LDL did.
Is high cholesterol inflammatory?
Start with what plaque is made of. Atherosclerosis is the slow buildup of fatty plaque in artery walls. Scientists now consider it an inflammatory disease, because plaques are full of immune cells. They also hold a lot of oxidized LDL: LDL cholesterol that has been chemically damaged.
LDL is the "bad" cholesterol your doctor checks. CRP (C-reactive protein) is a protein your liver makes when there is inflammation in the body, and hs-CRP is a sensitive test that picks up low levels of it.
What does that damaged LDL do? A 2025 systematic review gathered studies of human cells exposed to it, and the pattern was fairly consistent. Oxidized LDL raised IL-1 beta in 3 of 4 studies, IL-6 in 4 of 6 and TNF-alpha in 4 of 6. All three are signals the immune system uses to turn inflammation up.
Cholesterol can also form tiny crystals. A 2024 meta-analysis of 20 studies with 3,388 people looked at an immune switch called the NLRP3 inflammasome. The switch and the signals it releases were linked to high-risk artery disease, and cholesterol crystals are among the things known to flip it on.
So the answer is yes, at the place that matters most. But the same 2025 review was blunt: there is a gap between what papers suggest oxidized LDL does and what studies have shown it does to blood vessel cells.
Does lowering cholesterol lower inflammation?
Sometimes, and not always for the reason you would guess.
On statins, hs-CRP predicted heart events and deaths better than LDL did.From a 2023 randomized trial in Lancet
A 2024 meta-analysis pooled 53 randomized trials of cholesterol-lowering drugs. Statins, ezetimibe, bempedoic acid and omega-3 fats all lowered CRP compared with placebo. But a newer class of injectable drugs, PCSK9 inhibitors, raised CRP slightly, even though they lower LDL a lot.
The telling part: across all those trials, how much LDL fell had no clear link to how much CRP fell. The authors concluded that the CRP drop happened apart from the LDL drop. If LDL were the main thing driving the inflammation in your blood, the two should have moved together. They did not.
Which matters more for heart disease?
Both, and that is the real headline.
Lowering LDL protects the heart. A 2024 meta-analysis of 60 randomized trials, with 408,959 people, found fewer major heart and stroke events for every step down in LDL. In people who already had heart disease, that benefit held steady over time.
But inflammation carries its own risk. A 2023 analysis in The Lancet followed patients from three large trials who were all taking statins. Those with the highest hs-CRP were more than twice as likely to die of heart disease as those with the lowest. LDL, by contrast, was not linked to major heart events in that group once they were on statins. The authors wrote that inflammation was the stronger predictor.
The American College of Cardiology agreed in a 2025 statement. High hs-CRP stays strongly predictive of repeat events even in people on statins. In healthy people, high hs-CRP flags a higher-risk group in whom statins lower the chance of a first heart attack or stroke, even when LDL is normal. The link between inflammation and artery disease, the statement says, is "no longer exploratory."
Can calming inflammation protect the heart?
This was the big open question. If inflammation matters, then lowering it, without touching cholesterol, should help.
A 2017 trial tested that. It enrolled 10,061 people who had had a heart attack and still had an hs-CRP of 2 or more. They got placebo or a drug that blocks IL-1 beta, an inflammation signal. The drug did not lower cholesterol at all. Yet at the 150-mg dose, people had fewer repeat heart attacks, strokes and heart deaths over a median of 3.7 years. There was a cost: more deaths from infection than with placebo.
Colchicine, an old, low-cost anti-inflammatory pill, was tested next. A 2025 meta-analysis of six randomized trials in people with known artery disease found fewer major heart and stroke events with colchicine than placebo, with no clear rise in safety problems.
Not every anti-inflammatory drug has worked in heart trials, and the cardiology statement warns against broad use of others until trials show they help.
Can inflammation affect cholesterol levels?
The arrow can point the other way, at least in severe illness. In a 2018 review of 29 studies in very sick hospital patients, including people with sepsis, cholesterol dropped as inflammation rose. That is far from the slow, low-level inflammation of heart disease. Still, it shows the two systems talk.
What this means for you
Tick what you'll try this week. Your picks stay on this device.
you take a statin or any other heart or cholesterol medicine (keep taking it as prescribed; do not stop it because of what you read about inflammation); you have had a heart attack, stroke or stent; you have a family history of very high cholesterol; or you are thinking about plant sterols or omega-3 pills alongside your medicines.
One tap. Results appear once 50 readers have voted, and the count is always real.
The bottom line
Picture an artery wall: damaged LDL sitting in a plaque, immune cells gathered around it, crystals flipping an inflammation switch. That is where high cholesterol and inflammation meet. Yet they are not one dial. Statins lower CRP apart from LDL, a drug that blocked inflammation cut heart events without touching cholesterol, and on statins, hs-CRP still tracked risk. Treat them as two numbers on the same team. Know both, and work on both.
Common questions
Does high cholesterol lead to inflammation?
Inside artery walls, it can contribute. Plaques hold damaged LDL, and in lab studies that LDL raised inflammation signals such as IL-6 in 4 of 6 studies. Cholesterol crystals can also switch on an immune sensor linked to high-risk plaque. But in 53 drug trials, changes in LDL did not track changes in CRP, so cholesterol is not the whole story.
Can inflammation affect cholesterol levels?
Yes, at least in severe illness. A review of 29 studies in very sick hospital patients with body-wide inflammation, including sepsis, found lower total cholesterol, LDL and HDL, and the shift grew with the level of inflammation. Whether the low, steady inflammation of everyday life changes cholesterol much is less clear from these studies.
Is cholesterol an inflammatory response?
Not exactly. Cholesterol is a fat your body needs and carries in particles like LDL. The inflammation happens when LDL builds up and gets damaged in artery walls, where it draws in immune cells. Scientists call the plaque itself an inflammatory disease, but cholesterol and inflammation are measured, and treated, as separate risks.
Do statins lower inflammation?
Yes, in trials. A 2024 meta-analysis of 53 randomized trials found statins lowered CRP compared with placebo, and that drop was not explained by how much LDL fell. Ezetimibe, bempedoic acid and omega-3 fats lowered CRP too. Whether that extra effect adds heart protection still needs more study, the authors wrote.
Ask the Research Desk
Heard something about inflammation you want checked? The best questions become articles, credited by first name only if you say yes.
How this article was made
Researched and written from 10 peer-reviewed papers. Our automated check matched every claim against the exact words of its source, confirmed every paper exists in PubMed, and found none retracted. Checked October 31, 2026. Not individually reviewed by a doctor. Photos are illustrative; the people in them are not patients or readers.
Grades run Strong, Moderate, Emerging, Early and Not supported, and the grade decides the words we may use. How we grade evidence · Medical disclaimer
Sources
- ReviewInflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.Mensah GA, Arnold N, Prabhu SD et al. J Am Coll Cardiol, 2026.PubMedFull paper
- Randomized trialInflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.Ridker PM, Bhatt DL, Pradhan AD et al. Lancet, 2023.PubMedFull paper
- Systematic reviewReview of OxLDL Driven Inflammatory Cell Activation.Ogugofor MO, Holmes D, Gieseg SP Curr Atheroscler Rep, 2025.PubMedFull paper
- Meta-analysisThe role of the NLRP3 inflammasome in atherosclerotic disease: Systematic review and meta-analysis.Khair M, Khair M, Vangaveti VN et al. J Cardiol, 2024.PubMedFull paper
- Meta-analysisEffect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials.Xie S, Galimberti F, Olmastroni E et al. Cardiovasc Res, 2024.PubMedFull paper
- Meta-analysisCourse of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials.Burger PM, Dorresteijn JAN, Koudstaal S et al. Atherosclerosis, 2024.PubMedFull paper
- Randomized trialAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.Ridker PM, Everett BM, Thuren T et al. N Engl J Med, 2017.PubMedFull paper
- Meta-analysisLong-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.Samuel M, Berry C, Dubé MP et al. Eur Heart J, 2025.PubMedFull paper
- Systematic reviewLipid profile associated with the systemic inflammatory response syndrome and sepsis in critically ill patients.Golucci APBS, Marson FAL, Ribeiro AF et al. Nutrition, 2018.PubMedFull paper
- Meta-analysisPortfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials.Chiavaroli L, Nishi SK, Khan TA et al. Prog Cardiovasc Dis, 2018.PubMedFull paper
